Treatment of older adults with type 2 diabetes (T2D) is complex because they represent a
heterogeneous group with a broad range of comorbidities, functional abilities …

Diabetes is a major and costly health concern worldwide, with high morbidity, disability,
mortality, and impaired quality of life. The vast majority of people living with diabetes have …

Aim: This guideline is aimed at providing a reference for the pharmacological and non-
pharmacological treatment of type 2 diabetes in adults. Methods: These recommendations …

Objectives To identify and assess the quality and accuracy of prognostic models for
nephropathy and to validate these models in external cohorts of people with type 2 diabetes …

With increasingly large sample sizes required to demonstrate event reduction, heart failure
outcome trials are no longer being performed in a small group of selected patients and …

Background We investigated the causal associations between the genetic liability to
cardiovascular and lifestyle risk factors and peripheral artery disease (PAD), using a …

Abstract EMPA-REG OUTCOME and CANVAS trials were designed to study the
cardiovascular safety of empagliflozin and canagliflozin, respectively. Both studies were …

Stroke remains the second leading cause of death in the world, and its prevalence is
projected to rise in the United States and globally. The main driver for increased stroke …

Background The optimal glycaemic control target in pregnant women with pre‐existing
diabetes is unclear, although there is a clear link between high glucose concentrations and …

Objectives: Guidance to industry from the FDA requires studies to evaluate the
cardiovascular safety of novel type 2 diabetes (T2D) medications. Although the objectives of …